Want to see GB:ABDX full AI Analyst Report?
Abingdon Health PLC (ABDX) AI Stock Analysis
Top Page
Abingdon Health PLC
(LSE:ABDX)
Positive earnings call guidance and revenue growth provide primary support, while cash flow weakness, negative valuation, and bearish technicals cap the overall score.
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 22.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 109.20K
- Price to Earnings (P/E)
- -16.4
- Beta (1Y)
- -0.30
- Revenue Growth
- 30.42%
- EPS Growth
- 43.16%
- Country
- UK
- Employees
- 113
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Abingdon Health PLC Business Overview & Revenue Model
Company Description
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-actin...
Abingdon Health PLC Earnings Call Summary
The call was predominantly positive. Management highlighted 30% revenue growth, a 47.1% gross margin, a first-half-year adjusted EBITDA profit in H2, 41% compound revenue growth from FY2023 to FY2026, expanding U.K. and U.S. capabilities, and strong contract visibility. The main negatives were the full-year adjusted EBITDA loss, operating cash outflow, flat contract manufacturing revenue, Q1 program delays, contract uncertainty, and a short-term revenue impact from restructuring. Management nevertheless expects revenue and EBITDA performance to improve in FY2027.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For financial year '27, management said revenue and adjusted EBITDA will be moved towards the second half, with revenue weighted more towards H2 due to a couple of delays in H1; the Board expects an improved EBITDA position for '27 versus '26, expects revenue to continue to increase, and expects EBITDA performance to improve over last year into this. The U.S. business is expected to generate revenue in the “sort of millions rather than hundreds of thousands” and management would like to see that “step up significantly in the future.” The integration of regulatory services may cause a short-term revenue impact, with a smaller impact on EBITDA, which management expects “to pick back up pretty quickly”; management also said it is “comfortable saying we think we're on for significant growth this year.”
Abingdon Health PLC Financial Statement Overview
Summary
Strong revenue growth to £11M and gross margin improvement to 47%, with stable balance sheet and low debt-to-equity of 0.22, offset by ongoing cash burn and unprofitability.
Income Statement
68PositiveBalance Sheet
78PositiveCash Flow
42Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.99M | 10.99M | 8.43M | 6.13M | 4.04M | 2.83M |
| Gross Profit | 5.18M | 5.18M | 3.13M | 3.68M | 1.40M | -5.23M |
| EBITDA | -2.13M | -2.13M | -3.12M | -916.00K | -2.81M | -19.98M |
| Net Income | -2.13M | -2.13M | -3.42M | -1.27M | -3.47M | -21.26M |
Balance Sheet | ||||||
| Total Assets | 10.81M | 10.81M | 9.31M | 5.09M | 6.06M | 12.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 2.87M | 1.92M | 1.44M | 3.24M | 2.40M |
| Total Debt | 1.34M | 1.34M | 1.03M | 1.05M | 1.02M | 1.28M |
| Total Liabilities | 4.71M | 4.71M | 4.01M | 2.84M | 3.05M | 6.34M |
| Stockholders Equity | 6.10M | 6.10M | 5.30M | 2.25M | 3.01M | 6.43M |
Cash Flow | ||||||
| Free Cash Flow | -1.79M | -1.79M | -3.43M | -1.70M | 845.00K | -8.49M |
| Operating Cash Flow | -1.60M | -1.60M | -3.10M | -1.66M | 1.00M | -7.74M |
| Investing Cash Flow | -357.00K | -357.00K | -1.43M | -23.00K | -156.00K | -760.00K |
| Financing Cash Flow | 2.95M | 2.95M | 5.08M | -114.00K | -7,000 | 5.92M |
Abingdon Health PLC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ABDX, the sentiment is Negative. The current price of 9.00 is below the 20-day moving average (MA) of 9.56, below the 50-day MA of 10.29, and below the 200-day MA of 9.49, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 14.25 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ABDX.
Abingdon Health PLC Peers Comparison
Overall Rating
GB:NIOX68Neutral
GB:EKF64Neutral- GB:ABDX60Neutral
GB:GDR49Neutral
GB:CNSL45Neutral
GB:RENX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:NIOX | 68Neutral | GBP 273.94M | 40.48 | 10.01% | 2.29% | 3.26% | 32.54% |
| GB:EKF | 64Neutral | GBP 102.71M | 41.38 | 3.58% | ― | 2.26% | -57.04% |
| GB:ABDX | 60Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:CNSL | 45Neutral | GBP 3.69M | -0.63 | -69.62% | ― | -16.27% | -471.21% |
| GB:RENX | 40Underperform | GBP 36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:ABDX | Abingdon Health PLC | 9.00 | 2.75 | 44.00% | |
| GB:NIOX | Circassia Pharmaceuticals | 67.60 | 1.31 | 1.98% | |
| GB:EKF | EKF Diagnostics Holdings | 24.00 | -2.20 | -8.40% | |
| GB:GDR | Genedrive plc | 0.97 | 0.01 | 1.25% | |
| GB:CNSL | Omega Diagnostics | 1.55 | -1.10 | -41.51% | |
| GB:RENX | Renalytix Plc OTC | 5.45 | -1.93 | -26.15% |
Abingdon Health PLC Corporate Events
Abingdon Health Delivers Double-Digit Growth and Achieves H2 EBITDA Profitability
PositiveAbingdon Health reported a strong FY26, with total revenues rising 32% to £11.3m and a transition to adjusted EBITDA profitability in the second half, driven by a 56% surge in contract development revenue and improving gross margins. The group a...
Abingdon Health posts 32% revenue rise and reaches H2 EBITDA profitability
PositiveAbingdon Health reported a strong FY26, with total revenues rising 32% to £11.3m and reported revenue up 30% to £11.0m, driven by a 56% jump in contract development income and improved gross margin to 47.1%. The group achieved adjusted EBIT...
Abingdon Health to unveil 2026 results with live investor briefing
PositiveAbingdon Health plc, a UK-headquartered med-tech services group specializing in rapid diagnostic tests and regulatory support, will release its final results for the year ended 30 June 2026 on 13 October 2026. The company operates CDMO, regulatory co...
Abingdon Health Wins UKAS ISO/IEC 17025 Accreditation for Diagnostic Testing Lab
PositiveAbingdon Health plc has secured ISO/IEC 17025:2017 accreditation from UKAS for Abingdon Analytical Ltd, its performance evaluation laboratory in Doncaster, England. The certification confirms the lab’s capability to deliver consistently valid a...
Abingdon Health Opens U.S. Manufacturing Hub to Expand Rapid Diagnostics Footprint
PositiveAbingdon Health plc has officially opened a new manufacturing hub at its facility in Madison, Wisconsin, marking a significant expansion of its U.S. operations. The site at University Research Park increases infrastructure and capacity to deliver hig...
Abingdon Health to Host Shareholder Open Day at York Headquarters
PositiveAbingdon Health PLC, a York-headquartered med-tech CDMO and regulatory services provider for rapid diagnostic tests, is expanding engagement with its international shareholder base through an in-person event. The business develops and manufactures la...
Abingdon Health posts 31% revenue rise and H2 EBITDA profitability
PositiveAbingdon Health PLC, a specialist in rapid diagnostic test development and manufacturing, has built an integrated CDMO and regulatory services platform that supports international customers from concept through to commercial-scale production. With op...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026